drugset / Trial / NCT04183062

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

NCT04183062 ↗

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2 study of an investigational drug, BIO-11006, for the treatment of lung metastases in pediatric patients with advanced osteosarcoma or Ewing's sarcoma. This study will enroll up to 10 patients aged between 5 and 21 at Nicklaus Children's Hospital in Miami, FL. Patients will receive BIO-11006 in addition to chemotherapy consisting of gemcitabine and docetaxel. This study will test the hypothesis that BIO-11006 will enhance the effect of the gemcitabine and docetaxel chemotherapy to treat lung metastases in osteosarcoma and Ewing's sarcoma.

Timeline

Start
2019-10-04
Primary completion
2019-10-04
Completion
2021-12-12

Outcome

Outcome not reported

Stopped (Enrollment): “The drug for this study was not available by the manufacturer. No patients enrolled.”

Drugs

EvaluationDrugModalityDoseRoute
Subject BIO-11006 Peptide 75 mg Inhaled
Subject BIO-11006 Peptide 125 mg Inhaled
Background Docetaxel Small molecule 75 mg/m2 Intravenous
Background Gemcitabine Small molecule 900 mg/m2 Intravenous